Traders should monitor near-term revenue recognition from the U.S. and Canadian contracts, particularly the $35M+ CAD expected in 2026. The recurring nature of international orders suggests potential for further demand, supporting valuation upside in a low-market-cap biodefense play.
EBS drugs
EBS drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 26 $8.08entry
- T+1 · 8mo ago −1.86%α −0.18% · $7.93
- T+5 · 8mo ago +1.86%α +0.22% · $8.23
- T+20 · 7mo ago −0.62%α −11.28% · $8.03
- T+60 · 5mo ago −1.73%α −15.68% · $7.94
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Emergent BioSolutions announced a $54 million contract extension with the U.S. government for VIGIV, a treatment for smallpox vaccine complications, and $6.6 million in new international orders for its ACAM2000 smallpox vaccine. These contracts reinforce the company's role in global biodefense preparedness and follow recent agreements with Canada worth up to $140 million CAD.
Key Financial Metrics
Key Facts
- Secured $54 million USD U.S. government contract (ASPR) for CNJ-016® (VIGIV) under an existing 10-year agreement
- Received $6.6 million USD in new international orders for ACAM2000® smallpox vaccine from a recurring customer
- Recent multi-year agreements with Government of Canada valued up to $140 million CAD, with over $35 million CAD expected in 2026
- Contracts support national and global biodefense strategies amid rising biological threat concerns
Financial Impact
$60.6 million in new or incremental contract awards (including $54M U.S. and $6.6M international); over $35M CAD (~$25.5M USD) expected revenue in 2026 from Canada
Risk Factors
- Revenue recognition timing may be back-end loaded or dependent on delivery milestones
- Forward-looking statements subject to execution risk and government procurement delays
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3262595 |
Track record
23 reports on EBS
3 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +14.89% at T+20 after the Apr 29, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 16, 2026today Institutional Cluster Neutral 3/10 Entry $5.76 Now $5.81 +0.96% settles Nov 23
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $5.75 Now $5.81 +1.13% settles Nov 23
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $5.79 Now $5.81 +0.35% settles Nov 23
- Nov 4, 202612d ago 8-K Neutral 4/10 Entry $5.85 to $5.89 Now $5.81 −0.68% ▲ +0.68% −2.61% vs SPY
- Nov 2, 202614d ago 8-K Bearish 6/10 Entry $6.25 to $6.05 Now $5.81 +7.04% ▲ +3.20% +2.61% vs SPY
- Oct 30, 202617d ago Institutional Cluster Neutral 2/10 Entry $6.81 to $6.06 Now $5.81 −14.68% ▼ −11.01% −8.31% vs SPY
- Oct 16, 20264w ago 8-K Neutral 3/10 Entry $6.38 to $6.23 Now $5.81 −8.93% ▼ −2.35% −2.44% vs SPY
- Oct 7, 20265w ago 144 Neutral 2/10 Entry $6.81 to $7.18 Now $5.81 −14.68% ▲ +5.43% +5.71% vs SPY
- Jun 29, 202620w ago 8-K Bullish 5/10 Entry $8.46 to $8.18 Now $5.81 −31.32% ▼ −3.31% −4.70% vs SPY
- Jun 4, 202623w ago Press Release Neutral 2/10 Entry $8.44 to $8.39 Now $5.81 −31.16% ▼ −0.59% +1.96% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers